Long-term Safety and Clinical Benefit of Mepolizumab in Patients With the Most Severe Eosinophilic Asthma: The COSMEX Study

Khurana, Sandhya; Brusselle, Guy; H. Bel, Elisabeth; Mark FitzGerald, J.; Masoli, Matthew; Korn, Stephanie; Kato, Motokazu; C. Albers, Frank; Bradford, Eric; Gilson, M; G. Price, Robert; Humbert, Marc

doi:10.1016/j.clinthera.2019.07.007

Public

Long-term Safety and Clinical Benefit of Mepolizumab in Patients With the Most Severe Eosinophilic Asthma: The COSMEX Study

Published in Clinical Therapeutics • Aug 22, 2019

Authors:

Sandhya Khurana

Guy Brusselle

Elisabeth H. Bel

Abstract

PURPOSE: The goal of this study was to assess the long-term safety and efficacy of mepolizumab in patients with the most severe eosinophilic asthma. METHODS: This multicenter, open-label, long-term, Phase IIIb study (COSMEX [COSMOS Extension]; 201312/NCT02135692) enrolled patients from the 52-week, ...

Subject

Medicine

Mepolizumab

Asthma

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!